OC.08.1: Randomised Multicentre Pilot Double-Blind Placebo-Controlled Study of Evaluating the Efficacy and Safety of Mesalazine in the Prevention of Recurrence of Diverticulitis: Interim Analysis After 24-Month Follow-Up

Parente, F.; Bargiggia, S.; Prada, Alberto; Bortoli, A.; Giacosa, Attilio; Monti, Carlo; Germanà, B.; Galliani, E.; Ferrari, A; Secreto, P.; Casella, Giovanni; Miori, G.; Pretis, G. De

doi:10.1016/s1590-8658(11)60193-x

Cited by 2 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Endpoints Results Parente et al [2011] Eudragit L (DIV/01-04 trial) (pentacol 1.6 g/day × 10 days/months for 2 years)…”

Section: -Aminosalicylic Acidmentioning

confidence: 99%

Preventing recurrent acute diverticulitis with pharmacological therapies

Tursi

2013

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Acute diverticulitis of the colon represents a significant burden for national health systems, in terms of direct and indirect costs. Past guidelines claimed that recurrent episodes (two or more) of diverticulitis need surgery, but revised guidelines recommend an individualized approach to patients after an attack of acute diverticulitis. For these reasons, conservative treatment has become the preferred choice after an episode of diverticulitis. Thus, significant efforts are now being focused to identify the correct therapeutic approach to prevent diverticulitis relapses. Nonabsorbable antibiotics, 5-aminosalicylic acid and probiotics are currently being investigated in this way. The effectiveness and the future perspectives of these treatments are discussed herein.

show abstract

“…Endpoints Results Parente et al [2011] Eudragit L (DIV/01-04 trial) (pentacol 1.6 g/day × 10 days/months for 2 years)…”

Section: -Aminosalicylic Acidmentioning

confidence: 99%

Preventing recurrent acute diverticulitis with pharmacological therapies

Tursi

2013

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

“…44 The most recent trial found that mesalamine (514.7 ± 30.5 mg/d) was significantly better than placebo in reducing the risk of diverticulitis over a 40-month period, as well as the number of diverticulitis flares and the need for surgery. 45 The relative risk of diverticulitis was 2.47 times higher (95% CI 1.38-4.43) in the placebo group than in the mesalamine group.…”

Section: Mesalamine In Diverticulitismentioning

confidence: 99%

“…44 They commonly include the bacteria Bifidobacterium spp., Lactobacillus spp. and certain strains of E. coli, and the budding yeast Saccharomyces boulardii.…”

Section: Probioticsmentioning

confidence: 99%

“…and certain strains of E. coli, and the budding yeast Saccharomyces boulardii. 44 Probiotic microorganisms appear to have multiple modes of action, including inhibition of pathogen adherence, improving mucosal defence by enhancing the integrity of tight junctions, decreasing bacterial translocation, stimulation of immunoglobulin A secretion in Peyer patches and enhancement of immune system activity by controlling the balance of proand anti-inflammatory cytokines. 48 Probiotics may also interfere with pathogen metabolism 48 and have the ability to restore balance to enteric flora, primarily by decreasing the number of pathogenic gram-negative bacteria.…”

Section: Probioticsmentioning

confidence: 99%

“…1,2,[24][25][26][39][40][41][42][43][44][45][46][47]51 Box 2 provides an example of how this algorithm may work in practice.…”

Section: Probioticsmentioning

confidence: 99%

See 2 more Smart Citations